MSX1-A Potential Marker for Uterus-Preserving Therapy of Endometrial Carcinomas

Eppich, Simon; Kuhn, Christina; Schmoeckel, Elisa; Mayr, Doris; Mahner, Sven; Jeschke, Udo; Gallwas, Julia und Heidegger, Helene Hildegard (2020): MSX1-A Potential Marker for Uterus-Preserving Therapy of Endometrial Carcinomas. In: International Journal of Molecular Sciences, Bd. 21, Nr. 12, 4529

Abstract

Prognostic factors are of great interest in patients with endometrial cancer. One potential factor could be the protein MSX1, a transcription repressor, that has an inhibitory effect on the cell cycle. For this study, endometrioid endometrial carcinomas (n= 53), clear cell endometrial carcinomas (n= 6), endometrioid ovarian carcinomas (n= 19), and clear cell ovarian carcinomas (n= 11) were immunochemically stained for the protein MSX1 and evaluated using the immunoreactive score (IRS). A significant stronger expression of MSX1 was found in endometrioid endometrial carcinomas (p< 0.001), in grading 2 (moderate differentiation) (p= 0.001), and in tumor material of patients with no involvement of lymph nodes (p= 0.031). Correlations were found between MSX1 expression and the expression of beta-Catenin, p21, p53, and the steroid receptors ER alpha, ER beta, PR alpha, and PR beta. A significant (p= 0.023) better survival for patients with an MSX1 expression in more than 10% of the tumor cells was observed for endometrioid endometrial carcinomas (21.3 years median survival (MSX1-positive) versus 17.3 years (MSX1-negative)). Although there is evidence that MSX1 expression correlates with improved long-term survival, further studies are necessary to evaluate if MSX1 can be used as a prognostic marker.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• Sprache: Englisch